Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]
AN2 Therapeutics, Inc. (ANTX)
US:NYSE Investor Relations:
ir.antheminc.com
Company Research
Source: Yahoo! Finance
This market is expected to increase at a significant rate. LAS VEGAS Sept. 11, 2024 /PRNewswire/ -- DelveInsight's Nontuberculous Mycobacterial Infection Market Insights report includes a comprehensive understanding of current treatment practices, nontuberculous mycobacterial infection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into the United States Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report According to DelveInsight's analysis, the market size for nontuberculous mycobacterial infection was found to be USD 360 million in the US in 2023. The majority of the market share was of ARIKAYCE , with a revenue of approximately USD 223 million for refractory MAC. This figure is projected to grow further by 2034, driven by continued advancements in treatment and increasing awareness. According to DelveInsight's epidemiology model, the total diagnosed prevalent cases of NTM i
Show less
Read more
Impact Snapshot
Event Time:
ANTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANTX alerts
High impacting AN2 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ANTX
News
- AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaBusiness Wire
- AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
- AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics Adopts Limited Duration Stockholder Rights PlanBusiness Wire
ANTX
Earnings
- 8/13/24 - Beat
ANTX
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 3
- ANTX's page on the SEC website